Topical heparin for recurrent genital herpes simplex virus infections. A proposed model for subsequent therapeutic trials.

A randomized, prospective, placebo-controlled, double-blind study was done of topical heparin for recurrent genital herpes simplex virus (HSV) infections. Our experience can serve as a model for those interested in studying their own approaches to the outpatient treatment of genital HSV in virtually any clinical setting, from standard test dose clinic to private practice.